Association of lipoprotein-associated phospholipase A2 and risk of incident atrial fibrillation: Findings from 3 cohorts

Parveen K. Garg, Traci M. Bartz, Faye L. Norby, Neal W. Jorgensen, Robyn L. McClelland, Christie M. Ballantyne, Lin Y. Chen, John S. Gottdiener, Philip Greenland, Ron Hoogeveen, Nancy S. Jenny, Jorge Kizer, Robert S. Rosenson, Elsayed Z. Soliman, Mary Cushman, Alvaro Alonso, Susan R. Heckbert

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background Multiple prospective studies have established an association between inflammation and higher risk of atrial fibrillation (AF), but the association between lipoprotein-associated phospholipase A2 (Lp-PLA2) mass and activity and incident AF has not been extensively evaluated. Methods Using data from 10,794 Atherosclerosis Risk In Communities (ARIC) study participants aged 53-75 years, 5,181 Cardiovascular Health Study (CHS) participants aged 65 to 100 years, and 5,425 Multi-Ethnic Study of Atherosclerosis (MESA) participants aged 45-84 years, we investigated the association between baseline Lp-PLA2 levels and the risk of developing AF. Incident AF was identified in each cohort by follow-up visit electrocardiograms, hospital discharge coding of AF, or Medicare claims data. Results Over a mean of 13.1, 11.5, and 10.0 years of follow-up, 1,439 (13%), 2,084 (40%), and 615 (11%) incident AF events occurred in ARIC, CHS, and MESA, respectively. In adjusted analyses, each SD increment in Lp-PLA2 activity was associated with incident AF in both ARIC (hazard ratio [HR] 1.13, 95% CI 1.06-1.20) and MESA (HR 1.24, 95% CI 1.05-1.46). Each SD increment in Lp-PLA2 mass was also associated with incident AF in MESA (HR 1.25, 95% CI 1.11-1.41). No significant associations were observed among CHS participants. Conclusions Although higher Lp-PLA2 mass and activity were associated with development of AF in ARIC and MESA, this relationship was not observed in CHS, a cohort of older individuals.

Original languageEnglish (US)
Pages (from-to)62-69
Number of pages8
JournalAmerican Heart Journal
Volume197
DOIs
StatePublished - Mar 1 2018

Fingerprint

1-Alkyl-2-acetylglycerophosphocholine Esterase
Atrial Fibrillation
Atherosclerosis
Health
Medicare
Electrocardiography
Cohort Studies
Prospective Studies

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Garg, P. K., Bartz, T. M., Norby, F. L., Jorgensen, N. W., McClelland, R. L., Ballantyne, C. M., ... Heckbert, S. R. (2018). Association of lipoprotein-associated phospholipase A2 and risk of incident atrial fibrillation: Findings from 3 cohorts. American Heart Journal, 197, 62-69. https://doi.org/10.1016/j.ahj.2017.11.010

Association of lipoprotein-associated phospholipase A2 and risk of incident atrial fibrillation : Findings from 3 cohorts. / Garg, Parveen K.; Bartz, Traci M.; Norby, Faye L.; Jorgensen, Neal W.; McClelland, Robyn L.; Ballantyne, Christie M.; Chen, Lin Y.; Gottdiener, John S.; Greenland, Philip; Hoogeveen, Ron; Jenny, Nancy S.; Kizer, Jorge; Rosenson, Robert S.; Soliman, Elsayed Z.; Cushman, Mary; Alonso, Alvaro; Heckbert, Susan R.

In: American Heart Journal, Vol. 197, 01.03.2018, p. 62-69.

Research output: Contribution to journalArticle

Garg, PK, Bartz, TM, Norby, FL, Jorgensen, NW, McClelland, RL, Ballantyne, CM, Chen, LY, Gottdiener, JS, Greenland, P, Hoogeveen, R, Jenny, NS, Kizer, J, Rosenson, RS, Soliman, EZ, Cushman, M, Alonso, A & Heckbert, SR 2018, 'Association of lipoprotein-associated phospholipase A2 and risk of incident atrial fibrillation: Findings from 3 cohorts', American Heart Journal, vol. 197, pp. 62-69. https://doi.org/10.1016/j.ahj.2017.11.010
Garg, Parveen K. ; Bartz, Traci M. ; Norby, Faye L. ; Jorgensen, Neal W. ; McClelland, Robyn L. ; Ballantyne, Christie M. ; Chen, Lin Y. ; Gottdiener, John S. ; Greenland, Philip ; Hoogeveen, Ron ; Jenny, Nancy S. ; Kizer, Jorge ; Rosenson, Robert S. ; Soliman, Elsayed Z. ; Cushman, Mary ; Alonso, Alvaro ; Heckbert, Susan R. / Association of lipoprotein-associated phospholipase A2 and risk of incident atrial fibrillation : Findings from 3 cohorts. In: American Heart Journal. 2018 ; Vol. 197. pp. 62-69.
@article{0d0854b6a7474ef49d98776e901faf2e,
title = "Association of lipoprotein-associated phospholipase A2 and risk of incident atrial fibrillation: Findings from 3 cohorts",
abstract = "Background Multiple prospective studies have established an association between inflammation and higher risk of atrial fibrillation (AF), but the association between lipoprotein-associated phospholipase A2 (Lp-PLA2) mass and activity and incident AF has not been extensively evaluated. Methods Using data from 10,794 Atherosclerosis Risk In Communities (ARIC) study participants aged 53-75 years, 5,181 Cardiovascular Health Study (CHS) participants aged 65 to 100 years, and 5,425 Multi-Ethnic Study of Atherosclerosis (MESA) participants aged 45-84 years, we investigated the association between baseline Lp-PLA2 levels and the risk of developing AF. Incident AF was identified in each cohort by follow-up visit electrocardiograms, hospital discharge coding of AF, or Medicare claims data. Results Over a mean of 13.1, 11.5, and 10.0 years of follow-up, 1,439 (13{\%}), 2,084 (40{\%}), and 615 (11{\%}) incident AF events occurred in ARIC, CHS, and MESA, respectively. In adjusted analyses, each SD increment in Lp-PLA2 activity was associated with incident AF in both ARIC (hazard ratio [HR] 1.13, 95{\%} CI 1.06-1.20) and MESA (HR 1.24, 95{\%} CI 1.05-1.46). Each SD increment in Lp-PLA2 mass was also associated with incident AF in MESA (HR 1.25, 95{\%} CI 1.11-1.41). No significant associations were observed among CHS participants. Conclusions Although higher Lp-PLA2 mass and activity were associated with development of AF in ARIC and MESA, this relationship was not observed in CHS, a cohort of older individuals.",
author = "Garg, {Parveen K.} and Bartz, {Traci M.} and Norby, {Faye L.} and Jorgensen, {Neal W.} and McClelland, {Robyn L.} and Ballantyne, {Christie M.} and Chen, {Lin Y.} and Gottdiener, {John S.} and Philip Greenland and Ron Hoogeveen and Jenny, {Nancy S.} and Jorge Kizer and Rosenson, {Robert S.} and Soliman, {Elsayed Z.} and Mary Cushman and Alvaro Alonso and Heckbert, {Susan R.}",
year = "2018",
month = "3",
day = "1",
doi = "10.1016/j.ahj.2017.11.010",
language = "English (US)",
volume = "197",
pages = "62--69",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Association of lipoprotein-associated phospholipase A2 and risk of incident atrial fibrillation

T2 - Findings from 3 cohorts

AU - Garg, Parveen K.

AU - Bartz, Traci M.

AU - Norby, Faye L.

AU - Jorgensen, Neal W.

AU - McClelland, Robyn L.

AU - Ballantyne, Christie M.

AU - Chen, Lin Y.

AU - Gottdiener, John S.

AU - Greenland, Philip

AU - Hoogeveen, Ron

AU - Jenny, Nancy S.

AU - Kizer, Jorge

AU - Rosenson, Robert S.

AU - Soliman, Elsayed Z.

AU - Cushman, Mary

AU - Alonso, Alvaro

AU - Heckbert, Susan R.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Background Multiple prospective studies have established an association between inflammation and higher risk of atrial fibrillation (AF), but the association between lipoprotein-associated phospholipase A2 (Lp-PLA2) mass and activity and incident AF has not been extensively evaluated. Methods Using data from 10,794 Atherosclerosis Risk In Communities (ARIC) study participants aged 53-75 years, 5,181 Cardiovascular Health Study (CHS) participants aged 65 to 100 years, and 5,425 Multi-Ethnic Study of Atherosclerosis (MESA) participants aged 45-84 years, we investigated the association between baseline Lp-PLA2 levels and the risk of developing AF. Incident AF was identified in each cohort by follow-up visit electrocardiograms, hospital discharge coding of AF, or Medicare claims data. Results Over a mean of 13.1, 11.5, and 10.0 years of follow-up, 1,439 (13%), 2,084 (40%), and 615 (11%) incident AF events occurred in ARIC, CHS, and MESA, respectively. In adjusted analyses, each SD increment in Lp-PLA2 activity was associated with incident AF in both ARIC (hazard ratio [HR] 1.13, 95% CI 1.06-1.20) and MESA (HR 1.24, 95% CI 1.05-1.46). Each SD increment in Lp-PLA2 mass was also associated with incident AF in MESA (HR 1.25, 95% CI 1.11-1.41). No significant associations were observed among CHS participants. Conclusions Although higher Lp-PLA2 mass and activity were associated with development of AF in ARIC and MESA, this relationship was not observed in CHS, a cohort of older individuals.

AB - Background Multiple prospective studies have established an association between inflammation and higher risk of atrial fibrillation (AF), but the association between lipoprotein-associated phospholipase A2 (Lp-PLA2) mass and activity and incident AF has not been extensively evaluated. Methods Using data from 10,794 Atherosclerosis Risk In Communities (ARIC) study participants aged 53-75 years, 5,181 Cardiovascular Health Study (CHS) participants aged 65 to 100 years, and 5,425 Multi-Ethnic Study of Atherosclerosis (MESA) participants aged 45-84 years, we investigated the association between baseline Lp-PLA2 levels and the risk of developing AF. Incident AF was identified in each cohort by follow-up visit electrocardiograms, hospital discharge coding of AF, or Medicare claims data. Results Over a mean of 13.1, 11.5, and 10.0 years of follow-up, 1,439 (13%), 2,084 (40%), and 615 (11%) incident AF events occurred in ARIC, CHS, and MESA, respectively. In adjusted analyses, each SD increment in Lp-PLA2 activity was associated with incident AF in both ARIC (hazard ratio [HR] 1.13, 95% CI 1.06-1.20) and MESA (HR 1.24, 95% CI 1.05-1.46). Each SD increment in Lp-PLA2 mass was also associated with incident AF in MESA (HR 1.25, 95% CI 1.11-1.41). No significant associations were observed among CHS participants. Conclusions Although higher Lp-PLA2 mass and activity were associated with development of AF in ARIC and MESA, this relationship was not observed in CHS, a cohort of older individuals.

UR - http://www.scopus.com/inward/record.url?scp=85039994915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039994915&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2017.11.010

DO - 10.1016/j.ahj.2017.11.010

M3 - Article

C2 - 29447785

AN - SCOPUS:85039994915

VL - 197

SP - 62

EP - 69

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

ER -